Seagen, Genmab See Broad Cervical Cancer Opportunity For Tisotumab Vedotin
US FDA Clears Monotherapy Use
At ESMO, data showed objective response benefit in combination with carboplatin in first-line therapy, and with Keytruda in second- or third-line treatment. The antibody-drug conjugate obtained US approval on 20 September as monotherapy.
